---
title: "Losartan Potassium 50 mg Tablet, a) 30-count blister card (NDC# 70518-3282-1)... — FDA record D-0788-2022 | Is It on Recall"
description: "CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits."
url: https://isitonrecall.com/recall/fda-drug-d-0788-2022-losartan-potassium-50-mg-tablet-a-30-count-blister-card-ndc-70518-3282-1-b-60-count-blister-card-ndc/
updated: 2026-10-01
site: "Is It on Recall"
language: en
---

[Recall archive](https://isitonrecall.com/archives/) / FDA drug enforcement

# Losartan Potassium 50 mg Tablet, a) 30-count blister card (NDC# 70518-3282-1), b) 60-count blister card (NDC: 70518-3... — FDA record D-0788-2022

Reported terminated

Status as reported in the agency record. FDA warns that enforcement status may not track the current recall lifecycle; check the current official notice.

Source date Apr 6, 2022. Retrieved Oct 1, 2026. Last updated Oct 1, 2026.

Archive changed Oct 1, 2026. USDA FSIS records are unavailable; [check FSIS directly](https://www.fsis.usda.gov/recalls). [Source coverage and dates](https://isitonrecall.com/sources/).

## What the record says

- **Product**: Losartan Potassium 50 mg Tablet, a) 30-count blister card (NDC# 70518-3282-1), b) 60-count blister card (NDC: 70518-3282-0), Rx Only, MFG by: Lupin Pharma, Baltimore, MD 21202.
- **Reason**: CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits.
- **Classification**: Class II
- **Recalling firm**: RemedyRepack Inc.
- **Quantity**: 433/30 count blister cards, 33/60 count blister cards
- **Agency-reported status**: Terminated
- **Source record identifier**: D-0788-2022

[Open the official record](https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0788-2022%22)

[What the recall classes mean](https://isitonrecall.com/guides/recall-classes/). Classification is an agency assessment, not individual medical advice.

## Lot and product identifiers

| Label field | Details supplied by the agency |
| --- | --- |
| Lot, code or applicability | Lot # B1467803-120621, exp. date 06/30/2022 Lot # J0585793-121721, exp. date 12/31/2022 |

Match all identifying details in the current notice. A brand name alone is not enough.

## Distribution

Product was distributed to customers in AK and PA.

States below are derived from the distribution text, including nationwide wording. They are not inferred from the firm's address.

- [Alaska](https://isitonrecall.com/state/alaska/)
- [Pennsylvania](https://isitonrecall.com/state/pennsylvania/)

## Dates in the source

- **Report date**: May 4, 2022
- **Recall initiation date**: Apr 6, 2022
- **Center classification date**: Apr 26, 2022
- **Termination date**: May 27, 2022

FDA company pages use the listing date; enforcement records use initiation dates; CPSC uses recall date; NHTSA uses report-received date. These dates are not interchangeable.

## What to do next

Read the official notice for the action that applies to your exact product.

[Read the current instructions](https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0788-2022%22)

## Before changing a medicine

Follow urgent instructions in the current official recall notice. Speak to your pharmacist or prescriber before stopping or changing a prescribed medicine.

Talk to your doctor or pharmacist if you have questions or concerns about your medicine. [FDA medication recall guidance](https://www.fda.gov/drugs/drug-recalls/understanding-drug-recalls-what-know-and-what-do)

## Related records

[Losartan records](https://isitonrecall.com/drug/losartan/) [Medications records](https://isitonrecall.com/category/medications/) [RemedyRepack Inc. records](https://isitonrecall.com/brand/remedyrepack-inc/)